Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax.

Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan José Rodríguez Sevilla Sangeetha Venugopal Samuel Urrutia Argueta Guillermo Montalban Bravo Koiji Sasaki Kelly Sharon Chien Danielle Hammond Rashmi Kanagal-Shamana Irene Gañán-Gómez Tapan Mahendra Kadia Gautam Borthakur Courtney D D DiNardo Naval G Daver Elias J Jabbour Farhad Ravandi Hagop M Kantarjian Guillermo Garcia Manero

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.

Keyphrases